Recent progress in large-scale separation techniques now allows reliable and reproducible purification of CD34 + cells from peripheral blood progenitor cell (PBPC) grafts and other hematopoietic stem cell sources. A new positive selection technique based on submicroscopic iron-dextran beads bound to monoclonal anti-CD34 antibody provides CD34
+ cells of particularly high purity, thus concomitantly leading to effective depletion of T lymphocytes by 4 to 5 log 10 in a single step procedure. 1, 2 The capacity of allogeneic positively selected CD34
+ hematopoietic progenitor cell transplants to reconstitute all hematopoietic cell lineages has been demonstrated in experimental animal models and several clinical studies. [3] [4] [5] [6] [7] [8] [9] Since acute graftversus-host disease (GVHD) is caused by mature alloreactive donor T cells and remains a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation, techniques for purification of CD34 + cells, which concomitantly allow ex vivo T cell depletion (TCD) below the threshold T cell numbers regarded as critical for the development of acute GVHD, represent a novel option for graft engineering aimed to prevent acute GVHD.
Previous experience with the clinical application of several techniques for negative selection of donor T lymphocytes from allogeneic marrow grafts in chronic phase chronic myeloid leukemia (CML) patients demonstrated that the risk of graft failure and leukemic recurrence is substantially increased as compared to unmanipulated marrow grafts. Although TCD effectively prevents acute GVHD and some of the limitations of this approach have been overcome by intensified conditioning regimens, by polyclonal or monoclonal antibodies directed against recipient cells mediating graft rejection, and by the application of donor T cells post transplant, the use of ex vivo T celldepleted marrow grafts has not convincingly improved clinical transplant results as compared to unmanipulated marrow grafts. 10 For several reasons, this situation may be different with the use of purified CD34
+ cells from mobilized PBPC. Firstly, PBPC grafts contain substantially higher numbers of hematopoietic progenitor cells, thus providing a better basis for ex vivo graft manipulation techniques with their inherent procedural cell losses. 11, 12 Secondly, higher numbers of transfused CD34
+ cells may diminish the risk of graft failure, and, in addition, may also reduce the risk of leukemic recurrence. Although the latter assumption has not been formally proven, recent clinical studies contain information to support this view: T cell-depleted PBPC grafts were shown to have a higher capacity to induce complete donor chimerism compared to T cell-depleted marrow grafts, also suggesting a more pronounced effect against residual leukemic recipient cells. 13 In addition, higher doses of CD34
+ cells were independently associated with a reduced risk of leukemic relapse after T cell-depleted hematopoietic stem cell transplantation. 14 Since the risk of residual malignant disease has been shown to be particularly high after TCD of HLA-identical sibling donor marrow grafts in CML patients, we conducted a prospective phase II study on allogeneic transplantation of HLA-identical sibling donor peripheral blood CD34
+ cells purified by magnetic-activated cell separation (MACS) in first chronic phase CML patients with special reference to graft engineering performance and follow-up studies of minimal residual disease (MRD) and cellular immune reconstitution.
Patients and methods

Study protocol
The study was conducted as a prospective clinical phase II study for eligible adult (18-60 years) Philadelphia chromosome (Ph)-positive first chronic phase CML patients, in whom an HLA-identical sibling donor had been identified. Patients and their respective donors were enrolled after the scientific background, details of the study protocol, as well as the potential benefits and hazards of treatment in the study had been explained and written informed consent to participate in this study had been obtained. The study protocol was approved by the Ethics Committee at the Medical Faculty of the University Hospital of Essen. Patient accrual was initiated in August 1998 and terminated in June 1999.
The primary study goal was to evaluate the performance of the CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) in purifying at least 5 × 10 6 CD34 + cells/kg of recipient body weight from allogeneic PBPC grafts. 1 Secondary study goals were to analyze engraftment, hematopoietic and immune reconstitution as well as MRD in patients with first chronic phase CML after transplantation of highly purified peripheral blood CD34
+ cells from HLA-identical sibling donors.
Patients and donors
Ten of 13 HLA-identical sibling pairs, who fulfilled the study inclusion criteria and were referred to our institution between August 1998 and June 1999, agreed to participate in the study. Patient and donor demographic characteristics are summarized in Table 1 .
Blood stem cell mobilization and collection
For PBPC mobilization, donors received 8 g/kg recombinant human granulocyte colony-stimulating factor (rh-G-CSF, Neupogen, Amgen-Roche, München, Germany) subcutaneously every 12 h for 4 to 6 days. Apheresis was performed on a continuous flow blood cell separator (Cobe Spectra, Cobe, München, Germany) equipped with software for semiautomated collection of mononuclear cells. The total duration of apheresis ranged between 2.9 and 9.8 (median 6.5) h in one (n = 3), two (n = 6), or three (n = 1) consecutive daily sessions, respectively. The median processed blood volume was 34.5 (range 16-56) l, which corresponds to a factor of 3.6-9.2 (median 6.7) of the calculated donor blood volume. All 18 aphereses in this study were performed by antecubital or forearm venous access.
Magnetic-activated cell separation
All apheresis products with at least 2 × 10 6 CD34 + cells/kg of recipient body weight were regarded as feasible for MACS. Depending on their cellular content, apheresis products were divided into 2 to 4 for a maximum of 4 × 10 8
CD34
+ cells per portion. Each portion was transferred to a 600 ml transfer bag with coupler (Baxter Fenwal, München, Germany) containing 500 ml phosphate-buffered saline supplemented with 5% v/v human serum albumin and 1 mm/l EDTA (PBS buffered) and then centrifuged at 500 g for 15 min. After washing, the supernatant was carefully drained to a residual volume of 95 ml. The cell pellet was resuspended and 7.5 ml of anti-CD34 antibody conjugated to iron-dextran microbeads (Miltenyi Biotech) were added to each bag. The cell suspension was then incubated at room temperature with continuous mixing for 30 min. Thereafter, cells were washed twice in 500 ml of PBS buffer at 500 g for 15 min, diluted to a final volume of 100 ml in PBS buffer, and transferred to the CliniMACS device. Prior to separation, the tubing set had been connected to a 1000 ml PBS buffer bag, a microaggregate blood transfusion filter (Pall Biomedical, Fajardo, PR, USA), and a 150 ml collection bag (Baxter Fenwal). After buffer priming of the tubing set, one bag with labeled cells was connected to the filter and the CD34 + cell separation was automatically performed by the inlet line and valve control program of the device. Aliquots of 0.5 ml were taken from the purified cell fraction for cell counts and flow cytometry analysis after separation.
Flow cytometry analysis
Samples from apheresis products and from the purified cell fractions were first diluted 1:10 and then quantified in a Coulter AC·8 cell counter (Beckman Coulter, Krefeld, Germany). The percentage of CD34
+ cells in these samples was determined by flow cytometry using a Coulter Epics III cytometer (Beckman Coulter). Briefly, 100 l of diluted cell samples were stained with anti-CD34-PE and anti-CD45-FITC (Becton Dickinson Immunocytometry Systems, Heidelberg, Germany) in a single tube. Isotypeidentical irrelevant PE-or FITC-conjugated antibodies were used as negative controls. After setting a polymorphic bitmap around cells in a forward-scatter vs log-side scatter histogram and gating out the non-specific fluorescence of control samples in PE-, FITC-and double-fluorescence histograms, simultaneous acquisition of 100 000 specific events was performed in one-and double-fluorescence histograms. Back-gating was used to confirm that the specific events were exclusively located within the bitmap around cells. The percentage of CD34 + cells was calculated by dividing the total number of PE-positive events by the number of FITC-positive events. For evaluation of CD34 + cell viability after separation, cells were simultaneously stained with anti-CD34-PE, anti-CD45-FITC, and the DNA-dye 7-aminoactinomycin-D (Molecular Probes, Leiden, The Netherlands). Since CD34
+ cell viability exceeded 99% in all purified cell fractions, no corrections according to the percentage of viable cells were necessary in calculating the number of CD34
+ cells. The absolute number of CD34 + cells in apheresis products and purified cell fractions was calculated as the product of % CD34 + cells × total white cell concentration × product volume. The number of CD3 + T lymphocytes in apheresis products and purified cell fractions was similarly determined by flow cytometry after staining with anti-CD3-PE (Beckman Coulter). Immunophenotyping of patient EDTA blood samples was performed according to methods previously described. 15 
MRD
Determination of major breakpoint cluster region Abelson fusion gene (M-bcr-abl) transcripts in peripheral blood or bone marrow samples by nested reverse transcriptase polymerase chain reaction (PCR) and cytogenetic evaluation of marrow samples for the detection of Ph positive cells were performed according to the published methods. 16 
Conditioning before transplant
All 10 patients were conditioned by fractionated total body irradiation delivered by a 60 Cobalt source at a daily dose of 2.5 Gy with a dose rate of 3 cGy/min on 4 consecutive days (day −7 to day −4 with day 0 being the day of first CD34 + cell transfusion). Lung shielding was used to reduce the total lung dose to 8 Gy. On days −3 and −2 patients additionally received 60 mg/kg cyclophosphamide followed by 5 mg/kg thiotepa, both applied as 1 h infusions. This protocol was amended after four patients by adding 4 × 10 mg/kg intravenous antithymocyte globulin (ATG Fresenius; Fresenius, Bad Homburg, Germany) between days −5 and −2.
GVHD prevention and growth factor application
With the exception of one patient, who additionally received two fractions of unseparated PBPC and was thereBone Marrow Transplantation fore treated with short-course methotrexate and cyclosporin A, no prophylactic post-transplant immunosuppression was used in this study. All patients received 5 g/kg continuous intravenous rh-G-CSF starting 1 day after the last CD34 + cell transfusion until blood neutrophil counts exceeded 500/l on 3 consecutive days.
Clinical evaluation and statistical analysis
Endpoints for the evaluation of hematopoietic regeneration were the first of 3 consecutive days on which blood neutrophil counts over 500/l and 1000/l had been attained or self-sustaining platelet counts exceeded 20 000/l and 50 000/l, respectively. Acute and chronic GVHD were diagnosed and graded according to commonly accepted criteria. The Bearman score was used to grade organ toxicities. 17 Quantitative measures were described by median (minimum and maximum) values. All analyses were performed on the intention-to-treat with no patient exclusions. The date of final analysis was 22 July 2000.
Results
CD34
+ cell purification performance
All but one donor mobilized sufficient numbers of CD34 + cells to allow successful CD34 + cell purification. Thus, 16 of the 18 apheresis products collected in this study were further processed by MACS. In Table 2 the results of separations for each apheresis product are given with regard to cell yields, CD34
+ cell purity and recovery, as well as CD3 + T lymphocyte depletion efficacy. The target cell dose of at least 5 × 10 6 CD34 + cells/kg of recipient body could be purified from a single apheresis product in eight (50%) separations, and 14 of the 16 (88%) separations resulted in purified CD34
+ cell doses Ͼ4 × 10 6 CD34 + cells/kg. Notably, all purified cell fractions contained less than 1 × 10 5 CD3 + T cells/kg of recipient body weight, and the median transfused CD3 + T cell dose was 1.0 (range 0.5-8.5) × 10 4 /kg, corresponding to a log 10 T cell depletion efficacy between 3.8 and 5 (Table 2) .
Hematologic recovery
Neutrophil recovery was rapid in all 10 patients with neutrophil counts Ͼ500/l occurring between 8 and 19 (median 8) days and Ͼ1000/l between 8 and 20 (median 9) days, respectively. Similarly, self-sustaining platelet counts Ͼ20 000/l were reached at a median of 12 (range 9-25) days and Ͼ50 000/l at a median of 14 (range 12-31) days, respectively (Table 3) . With the exception of the second patient (UPN 1165), in whom secondary graft failure developed 2 months post transplant, graft function remains stable with normal peripheral blood cell counts in the remaining nine patients. This patient received the lowest CD34 + dose, but the differences in CD34 + doses are too small to define a threshold dose of CD34 + cells sufficient for engraftment in our study population of 10 patients.
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+ cells in CML DW Beelen et al Cumulative numbers are given if two aphereses were needed to achieve a sufficient yield. a Two further apheresis products from the donor of patient number 1209 were transfused without CD34 + cell separation. b In separated products without detectable T cells by flow cytometry a log 10 depletion of 5.0 was assumed. 
GVHD
Three patients developed isolated skin involvement with acute GVHD of stages I (n = 1) or II (n = 2), which was successfully treated with phototherapy alone (n = 2) or in combination with low-dose steroids (n = 1). Two of the three patients (UPN 1134 and 1183) received T celldepleted PBPC transplants with T cell numbers below the median of 1 × 10 4 /kg body weight. The third patient (UPN 1165) developed acute GVHD after being retransplanted with an unmanipulated PBPC transplant for secondary graft failure. One patient developed isolated liver involvement and a second patient limited skin involvement with de novo chronic GVHD. Both patients had received unmanipulated PBPC transplants after graft failure (UPN 1165) or at the first transplant (UPN 1209) and were successfully treated with cyclosporin A alone. During the 4890 total patient days in this study, steroids and cyclosporin A were applied on 775 (16%) and 1054 (22%) patient days, respectively. This indirectly supports the fact that GVHD presented a minor problem in this study.
MRD
All 10 patients achieved a complete molecular and cytogenetic remission immediately after transplant. M-bcr-abl transcripts and Ph-positive cells reappeared early in one patient (UPN 1165) at the time of secondary graft failure. Four other patients (UPNs 1134, 1168, 1183, 1225) developed a molecular relapse at 15, 5, 10 and 7 months, respectively, and two of these patients (UPNs 1134, 1225) concomitantly relapsed cytogenetically (Figure 1 ). After treatment with donor lymphocyte infusions all four patients entered a second molecular remission.
Cellular immune reconstitution
Peripheral blood NK cell numbers increased rapidly in the first month post transplant and remained within normal ranges throughout the follow-up period. In contrast, the numbers of all other analyzed cellular components of the specific immune system remained below 100/l during the first month. Thereafter, cytotoxic T cells increased rapidly into the normal range and constituted the majority of TCR␣␤ T cells, while helper T cells did not reach the lower limit of normal after 1 year. This was mainly caused by a delayed reconstitution of 'naive' helper T cell numbers that remained below 100 cells/l throughout the follow-up period (Figure 2) . B cell numbers as well as serum concen- 
Clinical post-transplant course
With the exception of oropharyngeal mucositis (grade 1: n = 3, grade 2: n = 6, grade 3: n = 1), no acute organ toxicities were noted in this study. The median number of fever days during aplasia ranged between 2 and 15 (median 8) days and the median time interval between the first CD34 + cell transfusion and discharge from hospital was 17 (range 15-36) days. Four patients had to be readmitted during the post-transplant course. One patient with secondary graft failure (UPN 1165) underwent unmanipulated PBPC transplantation from the same donor. Another patient (UPN 1183) was laparoscopically splenectomized due to persisting splenomegaly and signs of hypersplenism at 4 months post transplant. Two patients (UPNs 1168, 1225) developed severe liver and gut involvement with acute GVHD after DLI. A total of three episodes of segmental varicella zoster virus infections was observed and successfully treated by intravenous acyclovir therapy. In seven patients at risk, no episode of cytomegalovirus reactivation Bone Marrow Transplantation has been documented so far by regular monitoring of quantitative antigenemia. No other infectious complications were noted in this study. With a median follow-up of 476 (range 351-680) days, all 10 patients are alive, eight patients present with a normal performance status, and seven patients are back at work.
Discussion
This prospective phase II study was conducted to analyze the performance of CD34 + cell purification using an automated clinical-scale separation device and to evaluate the feasibility of transplantation of highly purified HLA-identical sibling donor peripheral blood CD34
+ cells in adult patients with first chronic phase of CML.
As anticipated from a previous preclinical study using the identical technique in healthy volunteer donors, clinicalscale MACS separation led to reproducible and predictable results with regard to purity of blood-derived CD34 + cells and concomitantly allowed a log 10 T cell depletion efficacy between 4 and 5.
1 Notably, a target CD34 + cell dose Ͼ5 × 10 6 /kg could be purified in 50%, and Ͼ4 × 10 6 /kg in
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+ cells in CML DW Beelen et al nearly 90% of separations using a single apheresis product. The engraftment was even 5-7 days more rapid than seen with transplantation of unmanipulated PBPC with a standard immunosuppression using cyclosporin A and short course methotrexate. 13 However, whether these cell doses of highly purified CD34 + cells are sufficient for successful allogeneic transplantation between HLA-identical siblings is currently unclear. The fact that one patient in this study developed secondary graft failure after a CD34 + cell dose of nearly 8 × 10 6 /kg may point to the need for more vigorous pretransplant immunosuppression of the recipient to allow sustained engraftment of highly purified CD34 + cells in all patients. Consequently, we added antithymocyte globulin to the pretransplant conditioning regimen and no further graft failure has occurred in this study.
In the majority of previous clinical studies using different immunoadsorption or immunomagnetic techniques for separation of blood-derived allogeneic CD34
+ cells, the yield and purity of CD34 + cells as well as the T cell depletion efficacy appear substantially lower in comparison to the present results. [7] [8] [9] 11, 12, 18 Since the average number of transfused T cells exceeded 1 × 10 5 /kg of body weight as the threshold dose for the development of acute GVHD after HLA-identical sibling donor transplantation, post-transplant prophylactic immunosuppression has been generally used in these studies. 19 This was dispensable in the present study, because the T cell depletion resulted in T cell doses below 1 × 10 5 /kg in all transplants and the median number of transfused T cells was even one log 10 below this threshold. Acute GVHD of an overall clinical grade I developed in three patients in this study and could successfully be treated by intermittent phototherapy alone or in combination with low-dose steroids. Although GVHD could not be completely abrogated, the high efficacy of the present technique to prevent acute or chronic GVHD is best exemplified by the observation that steroids had to be applied merely during 16% of all patient days in this study.
Previous studies have demonstrated that T cell-depleted PBPC grafts have a higher potential to induce complete donor chimerism compared to T cell-depleted marrow grafts. 13, 20 This, together with results of a recent report which showed an inverse dose-response relationship between the transfused CD34 + cell numbers and the risk of leukemic relapse after T cell-depleted hematopoietic stem cell transplantation, suggests that higher numbers of highly purified blood-derived CD34 + cells may be able to counterbalance the adverse influence of TCD on leukemic relapse in CML patients observed after T cell-depleted sibling donor marrow transplantation.
14 This view is not supported by the results of the present study since M-bcr-abl transcripts reappeared in five patients despite a median CD34 + cell dose of about 10 × 10 6 /kg and two of these patients concomitantly relapsed cytogenetically. Sixteen months after transplantation, we would expect a molecular relapse rate of 7% after unmanipulated PBPC and of 32% after bone marrow transplantation at our institution and Ph positivity in almost no patients after unmanipulated PBPC and in 17% of patients after bone marrow transplantation. 16 B and T cell numbers were very low in the first weeks after transplantation with the lymphocyte population consisting mainly of NK cells. However, in contrast to transplantation of unmanipulated PBPC, B cell numbers and immunoglobulin levels returned to normal within 3 months, probably due to the fact that no prophylactic post-transplant immunosuppression had to be given. TCR␣␤ T cell numbers increased rapidly in the second month post transplant, but the shift to cytotoxic/suppressor T cells resolved only slowly over months. 'Memory' T cells reached numbers comparable to the recovery after unmanipulated PBPC transplantation at 6 to 9 months. Low numbers of 'naive' T cells were persisting more than 1 year. 21 Considering this delayed numerical T cell reconstitution and the rapid clearance of MRD which occurred in all five patients after DLI (in one patient together with a second graft), it appears that immunologic antileukemic effects of donor T cells play a key role after highly purified blood-derived CD34 + cell transplantation. In future developments using this technique it therefore seems mandatory to implement 'add-back' of donor T cells for patients with incipient CML relapse. In view of the otherwise uncomplicated clinical course and the very limited demand for post-transplant immunosuppressive treatment in the present study it appears worthwhile to compare such a concept to the transplantation of unmanipulated grafts.
In conclusion, the present study demonstrates that clinical-scale magnetic-activated separation of PBPC grafts allows reproducible and predictable purification of CD34 + cells, which concomitantly leads to effective T cell depletion. The clinical results obtained after transplantation of highly purified CD34
+ cells from HLA-identical sibling donors in patients with first chronic phase CML in this study challenge a comparison to the transplantation using unmodified PBPC grafts with conventional post-transplant immunosuppression.
